Trius Therapeutics, Inc. (TSRX)

[LongRun8]

True. Nobody knows when this whole discussion started, although, I would think it was picked up after discovery that small doses of tedizolid reduced the bacterial resistance against daptomycin.

Either way, I think the $13.50 is low or the $2 "bonus" payments could have been for more to get us near the market cap of $1 billion, which I think tedizolid would have accomplished by itself.

We can't forget that there are other things in TSRX's pipeline, too!